AdaptHealth (AHCO) Projected to Post Quarterly Earnings on Tuesday

AdaptHealth (NASDAQ:AHCO) is anticipated to announce its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $799.6240 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:30 AM ET.

AdaptHealth Price Performance

Shares of AHCO opened at $8.99 on Monday. The firm has a market cap of $1.22 billion, a PE ratio of 16.65, a P/E/G ratio of 1.11 and a beta of 1.72. The company has a current ratio of 1.06, a quick ratio of 0.82 and a debt-to-equity ratio of 1.14. The firm has a fifty day simple moving average of $9.15 and a two-hundred day simple moving average of $9.02. AdaptHealth has a 1-year low of $7.11 and a 1-year high of $11.63.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on AHCO shares. Wall Street Zen upgraded shares of AdaptHealth from a “buy” rating to a “strong-buy” rating in a research note on Sunday, October 19th. Zacks Research lowered shares of AdaptHealth from a “hold” rating to a “strong sell” rating in a research note on Friday, September 19th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of AdaptHealth in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.40.

Insider Activity at AdaptHealth

In other news, Director David Solomon Williams III sold 8,200 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $9.73, for a total value of $79,786.00. Following the completion of the sale, the director directly owned 50,045 shares in the company, valued at $486,937.85. This represents a 14.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On AdaptHealth

Hedge funds and other institutional investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. purchased a new stake in shares of AdaptHealth in the 2nd quarter worth $189,000. Ameriprise Financial Inc. boosted its holdings in AdaptHealth by 82.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,123,834 shares of the company’s stock worth $10,598,000 after buying an additional 509,255 shares during the period. AQR Capital Management LLC boosted its holdings in AdaptHealth by 64.7% in the 2nd quarter. AQR Capital Management LLC now owns 423,567 shares of the company’s stock worth $3,994,000 after buying an additional 166,359 shares during the period. Cerity Partners LLC bought a new position in AdaptHealth in the 2nd quarter worth $104,000. Finally, Jump Financial LLC bought a new position in AdaptHealth in the 2nd quarter worth $181,000. 82.67% of the stock is currently owned by hedge funds and other institutional investors.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.